Can gender difference in prescription drug use be explained by gender-related morbidity?: a study on a Swedish population during 2006. by Skoog, Jessica et al.
Skoog et al. BMC Public Health 2014, 14:329
http://www.biomedcentral.com/1471-2458/14/329RESEARCH ARTICLE Open AccessCan gender difference in prescription drug use
be explained by gender-related morbidity?: a
study on a Swedish population during 2006
Jessica Skoog1*, Patrik Midlöv1, Lars Borgquist2, Jan Sundquist1,3 and Anders Halling1,4Abstract
Background: It has been reported that there is a difference in drug prescription between males and females. Even
after adjustment for multi-morbidity, females tend to use more prescription drugs compared to males. In this study,
we wanted to analyse whether the gender difference in drug treatment could be explained by gender-related morbidity.
Methods: Data was collected on all individuals 20 years and older in the county of Östergötland in Sweden. The Johns
Hopkins ACG Case-Mix System was used to calculate individual level of multi-morbidity. A report from the Swedish
National Institute of Public Health using the WHO term DALY was the basis for gender-related morbidity. Prescription
drugs used to treat diseases that mainly affect females were excluded from the analyses.
Results: The odds of having prescription drugs for males, compared to females, increased from 0.45 (95% confidence
interval (CI) 0.44-0.46) to 0.82 (95% CI 0.81-0.83) after exclusion of prescription drugs that are used to treat diseases that
mainly affect females.
Conclusion: Gender-related morbidity and the use of anti-conception drugs may explain a large part of the difference
in prescription drug use between males and females but still there remains a difference between the genders at 18%.
This implicates that it is of importance to take the gender-related morbidity into consideration, and to exclude
anti-conception drugs, when performing studies regarding difference in drug use between the genders.
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Prescription of drugs is one of the health care system’s
most important methods to treat, relieve and sometimes
cure diseases. Nevertheless, prescription drug treatment
may carry risks such as adverse drug reactions, interac-
tions and polypharmacy [1], circumstances that may lead
to hospital admission [2,3]. Beyond the fact that treatment
with prescription drugs may cause patients to suffer from
side effects, these unwanted effects are the source of
substantial expenses to society. The total cost of pre-
scription drugs is very high. In 2012 the total drug cost
for prescription drugs in Sweden amounted to SEK 36
billion (≈ 3.6 billion Euros) [4]. Thus, on behalf of both* Correspondence: jessica.skoog@med.lu.se
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unless otherwise stated.the society and patients, it is important to keep the pre-
scription of drugs secure, effective and well motivated.
There are significant gender differences in health care
utilization and drug prescription between the genders
in Sweden, Europe and the United States. In general,
females use more prescription drugs [5-12] and more
health care than males [13-15]. In an earlier study we
showed that the gender difference in drug prescription
remains after adjustment for multi-morbidity. Males
had less than half the odds of having prescription drugs
compared to females despite adjustment for multi-
morbidity [16]. This indicates that factors other than
differences in multi-morbidity explain the higher pre-
scription rates among females. Still, if females are
afflicted to a higher extent than males with diseases that
are treated with prescription drugs, morbidity may still
explain the gender difference in drug prescription. Pre-
vious studies have shown that there is a differenceLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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with [17,18]. However, it has not yet been studied
whether this gender-related morbidity affects the pre-
scription of drugs. The main objective of this study was
to analyse whether the gender difference in drug treat-
ment observed after adjustment for multi-morbidity can
be explained by gender-related morbidity.
Methods
Study population
Data was collected in 2006 from the total population aged
20 years or older in the Swedish county of Östergötland,
which had about 400,000 residents in 2006. Östergötland
is situated 200 km southwest of Stockholm and the age
demographic matches that of the rest of Sweden [19]. Data
on the population’s age, gender and diagnoses in both
primary and secondary care was obtained from the Care
Data Warehouse in Östergötland (CDWÖ), a register con-
taining information on both public and private care. This
register has been described previously [20]. The study was
approved by the research ethics committee at Linköping
University (approval numbers 147/05 and 29/06).
Independent variable
Multi-morbidity was calculated using the Johns Hopkins
Adjusted Clinical Groups (ACG) Case-Mix System, a sys-
tem based on the theory that multi-morbidity corresponds
to a certain need for health care resources. This system is
based on the patients’ diagnoses recorded during a defined
period of time. The ethiology, duration, method of diagno-
sis, treatment and need of specialized care is considered
for every one of the patients’ diagnoses. The ACG Case-
Mix System has previously been described [21-24]. Indi-
viduals without need of health care according to the ACG
Case-Mix system are placed in Resource Utilization Band
0 (RUB 0) and individuals with a very high degree of need
for health care resources are placed in RUB 5. For
example, preventive interventions correspond to RUB 1, a
single chronic diagnosis could correspond to RUB 3 and a
certain combination of chronic diagnoses corresponds to
RUB 4 or RUB 5.
Dependent variable
The use (dichotomous variable) of prescription drug(s)
in 2006 was the dependent variable. Information con-
cerning the use of prescription drugs at the individual
level was acquired from the Swedish Prescribed Drug
Register, which is maintained by the National Board of
Health and Welfare. This register collects information
from the National Corporation of Swedish Pharmacies
(Apoteket AB). In 2006 Apoteket AB had a monopoly
on sales of prescription drugs and all prescription drugs
were tracked through Apoteket AB.The Anatomical Therapeutic Chemical (ATC) classifi-
cation system was elaborated by the WHO to enable
internationally comparable studies on prescription drugs.
Active substances are classified in different groups
according to the organ or system on which they act
and their therapeutic, pharmacological and chemical
properties. The drugs are divided into 14 main ATC
groups and these groups are subsequently divided into
five levels [25].
Over-the-counter drugs were not included in this study.
Analysis
We used a report from the Swedish National Institute
of Public Health to identify diseases that tend to afflict
females more frequently [17]. In the report, the disability-
adjusted life year (DALY) was used to measure the burden
of disease. The DALY concept was elaborated by the
WHO and the World Bank to measure the burden of dis-
ease in the population, taking into consideration both
mortality and disability [26-29]. The DALY is a time-based
measure that combines years of life lost due to premature
mortality and years spent living in states of less than full
health. DALYs are the sum of life years lost due to prema-
ture mortality and years lived with disability, adjusted for
severity. To put it simply, 1 DALY means one lost healthy
year. In the report from the Swedish National Institute of
Public Health, both major and minor gender differences
were identified. To ensure that the prevalence of the dis-
ease and the difference between the genders were high
enough to affect the results, we created two cut-off points.
We selected diseases that had at least 7,500 DALYs in
Sweden in 2006 for both genders combined and for which
the difference between the genders was at least 20%, with
a higher number of DALYs for females. Having identified
the diseases that tend to afflict females to a higher extent,
we identified the prescription drugs that are commonly
used to treat these specific diseases (Table 1) according to
Swedish National Guidelines [30,31]. Anti-conception that
is commonly used by healthy females as contraceptives is
a special case. These prescription drugs are not considered
to treat any disease but they may explain some of the
difference in prescription drug treatment between the
genders. Hence, these drugs were also identified as
drugs causing a difference in prescription drug treat-
ment between the genders.
Statistics
The prescription drugs used to treat the diseases that
afflict females to a higher extent, and anti-conception
drugs, were excluded from the analysis using logistic
regression. First, the prescription drugs were excluded
one by one in subsequent univariate analyses. In the
next step, the prescription drugs that caused a decrease
in the gender difference, i.e. the prescription drugs that
Table 1 ATC codes for the prescription drugs that are used to treat diseases and conditions that afflict females to a
greater extent than males
Disease or condition ATC code Prescription drug(s)
Anti-conception G03A Anti-conception drugs
Climacteric complaints (HRT) G03C Estrogens
G03D Gestagens
Thyroid gland disorders H03AA01 Thyroid hormones
Cystitis J01CA08 Pivmecillinam
J01EA01 Trimethoprim
J01XE01 Nitrofurantoin
Osteoarthritis M01 Anti-inflammatory and anti-rheumatic drugs
N02BE01 Paracetamol
Migraine N02C Migraine drugs, including triptans
Depression and anxiety disorders N05BA Benzodiazepines
N05BB01 Hydroxyzine
N05BE Buspirone
N06A Antidepressant drugs, including SSRIs
Insomnia N05CD Derivatives of benzodiazepines (e.g. nitrazepam)
N05CF Benzodiazepine-related drugs (e.g. zolpidem)
N05CM06 Propiomazine
Asthma and COPD R03AC Selective beta-2 stimulants and inhalable corticosteroids
R03AK
R03BA02
R03BA05
R03BB01
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univariate analyses, were excluded. The OR represents
the odds of having prescription drugs for males com-
pared to females.
We used STATA version 12 (Stata Corporation, Texas,
USA) for statistical analyses. Logistic regression was
used to examine the odds of having prescription drugs
in the study population, giving odds ratios (ORs and
95% confidence intervals (CIs). We generated three di-
chotomous models: Model 1 was adjusted for age and
multi-morbidity; Model 2 was adjusted for age, multi-
morbidity and relative ATC codes; and Model 3 was
adjusted for age, multi-morbidity and ATC codes that
gave an OR >0.45 when excluded in the univariate
analyses.
Logistic regression gives us the odds ratio of having
prescription drugs. For some diseases, it is highly likely
to receive more than one prescription drug. For example
in dementia, which afflicts females to a higher extent
than males, there is a strong likelihood that the patient
is using prescription drugs in addition to the prescrip-
tion drug used to treat the dementia. The prescription
drugs used to treat these diseases, for example dementia,
were not excluded in this study.Results
This study comprised 313,977 individuals at least 20 years
old. 66% of the population used at least one prescription
drug. Males used prescription drugs to a lesser degree
compared to females (Table 2).
The greatest gender differences in morbidity with
a preponderance for females were for the diagnoses
Depression and Anxiety disorders, Osteoarthritis, Migraine,
Insomnia, Asthma and COPD, Thyroid gland disorders and
Cystitis.
The gender difference in having prescription drugs was
greatest at young age and decreased with age (Table 3).
After adjustment for multi-morbidity, males had less
than half the odds of using prescription drugs com-
pared to females (OR 0.45 (95% CI 0.45-0.46)). After
excluding anti-conception drugs, the odds ratio in-
creased (OR 0.65 (95% CI 0.64-0.66)). The effect on the
odds ratios for other prescription drugs is shown in
Table 4. After excluding all the prescription drugs that
gave an odds ratio >0.45 when excluded in the univari-
ate analyses (“List of prescription drugs excluded in
Model 3”), the total OR of having prescription drugs
for males, compared to females, increased further to
0.82 (95% CI 0.80-0.83).
Table 2 Characteristics of the population’s prescription drug use
Prescription drug use in total population
Variables Yes No
N (%) N (%)
All 205827 (66) 108150 (35)
Gender Female 121682 (77) 37021 (23)
Male 84145 (54) 71129 (46)
Age 20-29 23916 (51) 23289 (49)
30-39 27666 (53) 24568 (47)
40-49 30419 (56) 24293 (44)
50-59 34946 (65) 19045 (35)
60-69 36745 (73) 11376 (34)
70-79 27643 (87) 4038 (13)
80- 24492 (94) 1541 (6)
Multi-morbidity level 0 26822 (26) 75013 (74)
1 30364 (69) 13491 (31)
2 51674 (80) 12913 (20)
3 82988 (93) 6595 (7)
4 10775 (99) 126 (1)
5 3204 (99.6) 12 (0.4)
N – Number of observations.
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Antidepressants
Benzodiazepines
Benzodiazepine-related drugs
Derivates of benzodiazepines
Hydroxyzine
Migraine drugs
Nitrofurantoin
Paracetamol
Propiomazine
Trimethoprim
Estrogens
Gestagens
Pivmecillinam
Thyroid hormones
Anti-conception drugsTable 3 Odds ratios of having prescription drugs for
males in different age categories after adjustment for
multi-morbidity
Age (years) OR (95% CI) P-value
20-39 0.32 (0.31-0.33) <0.001
40-59 0.52 (0.50-0.54) <0.001
60-79 0.60 (0.57-0.62) <0.001
80- 0.62 (0.55-0.69) <0.001Discussion
This study analysed morbidity-adjusted treatment with
prescription drugs. We found that the gender differ-
ence in prescription drug use may to a large part be ex-
plained by gender-related morbidity, but there is still a
gender difference at 18% that has not been explained.
After adjustment for age and multi-morbidity, the odds
of having prescription drugs for males, compared to
females, was 0.45. After adjustment for age, multi-
morbidity and prescription drugs used to treat diseases
that afflict females to a higher extent than males, the
odds ratio of having prescription drugs for males in-
creased to 0.82.
Our study included the total population above 20 years
of age in Östergötland, a county representative of the
population in Sweden in terms of age [19].
The exclusion of anti-conception drugs had the stron-
gest effect on the results, causing the OR to increase
from 0.45 to 0.65. Since many healthy females use anti-
conception drugs, these drugs should not be included in
future studies comparing prescription drugs between
males and females.
We expected a strong effect when excluding prescrip-
tion drugs that are used to treat climacteric complaints,
but this exclusion only increased the OR from 0.45 to
0.47. This could partly be explained by more restrictive
prescription of hormone replacement therapy according
to new guidelines [32].
Table 4 Odds ratios of having prescription drugs for
males, compared to females, after adjustment for age,
multi-morbidity and relevant prescription drug in
univariate analyses (Model 2)
Prescription drug excluded
from the analysis
OR (95% CI) P-value
NSAIDs 0.44 (0.43-0.45) <0.001
Buspirone 0.45 (0.45-0.46) <0.001
Coxibs 0.45 (0.45-0.46) <0.001
Inhalable corticosteroids 0.45 (0.45-0.46) <0.001
Ipratropium 0.45 (0.45-0.46) <0.001
Selective beta-2 stimulants 0.45 (0.44-0.46) <0.001
Antidepressants 0.46 (0.45-0.47) <0.001
Benzodiazepines 0.46 (0.45-0.46) <0.001
Benzodiazepine-related drugs 0.46 (0.45-0.47) <0.001
Derivatives of benzodiazepines 0.46 (0.45-0.46) <0.001
Hydroxyzine 0.46 (0.45-0.46) <0.001
Migraine drugs 0.46 (0.45-0.47) <0.001
Nitrofurantoin 0.46 (0.45-0.47) <0.001
Paracetamol 0.46 (0.45-0.47) <0.001
Propiomazine 0.46 (0.45-0.46) <0.001
Trimethoprim 0.46 (0.45-0.47) <0.001
Estrogens 0.47 (0.46-0.48) <0.001
Gestagens 0.47 (0.46-0.48) <0.001
Pivmecillinam 0.47 (0.46-0.48) <0.001
Thyroid hormones 0.47 (0.46-0.48) <0.001
Anti-conception drugs 0.65 (0.64-0.66) <0.001
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the effects on the OR were small when analysing the ex-
clusion of prescription drugs one by one, but the overall
effect on the OR was substantial. Even though the effect
of each individual prescription drug was low, the aggre-
gative effect may be high if doctors commonly prescribe
these drugs to females.
We expected that the exclusion of prescription drugs
used to treat hormone-sensitive breast cancer would
lead to overestimation of the effect of gender-related
morbidity on the gender difference in drug prescription.
However, we estimated that the effect of including these
prescription drugs would be cancelled out by the effect
of prescription drugs used to treat prostate cancer [18].
After the adjustments made in this study there was
still a gender difference of 18% in prescription drug use,
with a higher prescription rate among females. This may
partly be explained by the fact that females have a higher
doctor consultation rate compared to males [13-15]. It
has also been shown that females tend to seek more pre-
ventive care compared to males, who seek emergency
care at a higher rate, which may indicate that females
seek health care earlier and have a higher likelihood ofhaving prescription drugs [15,33]. It is also possible that
the difference in prescription of drugs may be doctor-
related, as has been observed in recent studies [34,35].
The gender-related morbidity described in the re-
port from the Swedish National Institute of Public
Health that was the basis for this study comports well
with the gender-related morbidity seen in other stud-
ies [36-40]. In the present study, 66% of the study
population used prescription drugs, in line with other
studies [11,34,41].
This study shows that when comparing the pres-
cription of drugs between males and females, it is very
important to take into account gender-related morbidity.
Still, after adjustment for multi-morbidity and gender-
related morbidity, there remains a gender difference.
Thus, other factors than pure medical ones seem to
affect the prescription of drugs. Future research needs
to focus on that.
Limitations
Most of the diseases that females are afflicted with to a
higher extent in the report from the Swedish National
Institute of Public Health are diseases that may com-
monly be treated with only one prescription drug, i.e.
hypothyroidism, cystitis and migraine. Even if we used
Swedish guidelines when we identified the prescription
drugs that are used to treat diseases that females are
afflicted with to a higher extent [30,31] there is a risk
that the doctors do not follow guidelines. This could
lead to both under- and overestimation of the results
when prescription drugs with an indication for treat-
ment of diseases that females are afflicted with to a
higher extent are used for other purposes and vice versa.
As mentioned before, because of the logistic model for
example dementia was not included among the diseases
that affect females to a higher extent than males and
consequently the prescription drugs used to treat de-
mentia were not excluded from the study. This may have
led to lower ORs and underestimation of the effect of
gender-related morbidity on the gender difference in
drug prescription.
The chosen cut-off point for the number of DALYs
(7,500) may have been set too high and the chosen cut-
off point for gender difference in DALYs (20%) may have
been set too low. This may have led to underestimation
of the effect of gender-related morbidity on the gender
difference in drug prescription.
The classification of anti-conception drugs as pre-
scription drugs may differ between different countries.
In Sweden they are classified as prescription drugs and
are included in all prescription drug statistics. The re-
sults of the present study cannot be generalised to
countries where anti-conception drugs are not classified
as prescription drugs.
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Gender-related morbidity and the use of anti-conception
drugs may explain a large part of the difference in pre-
scription drug use between males and females but still
there remains a difference between the genders at 18%.
This implicates that it is of importance to take the
gender-related morbidity into consideration, and to
exclude anti-conception drugs, when performing studies
regarding difference in drug use between the genders.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JS drafted the manuscript and participated in the design of the study. PM, LB
and JST helped to draft the manuscript. AH performed the statistical analysis,
helped to draft the manuscript, handled the data set and designed the study.
All authors read and approved the final manuscript.
Acknowledgements
This study was supported by grants from the Swedish Governmental
Funding of Clinical Research within the Swedish Public Health System.
We are indebted to Stephen Gilliver for his expertise and advice in
proofreading the manuscript.
Author details
1Department of Clinical Sciences in Malmö, Center for Primary Health Care
Research, Lund University, SE-205 02 Malmö, Sweden. 2Department of
Medical and Health Sciences, General Practice, Linköping University, SE-581
83 Linköping, Sweden. 3Stanford Prevention Research Center, Stanford
University School of Medicine, Stanford, CA, USA. 4Research Unit for General
Practice, Institute of Public Health, University of Southern Denmark, J.B.
Winsløws Vej 9A, DK-5000 Odense C, Denmark.
Received: 16 November 2013 Accepted: 1 April 2014
Published: 8 April 2014
References
1. Petrovic M, van der Cammen T, Onder G: Adverse drug reactions in older
people: detection and prevention. Drugs Aging 2012, 29(6):453–462.
2. Fastbom J: Increased consumption of drugs among the elderly results in
greater risk of problems. Lakartidningen 2001, 98(14):1674–1679.
3. Cascorbi I: Drug interactions–principles, examples and clinical
consequences. Dtsch Arztebl Int 2012, 109(33–34):546–555. quiz 556.
4. Statistics prescription drugs expenses in Sweden in 2012. 2012. http://www.
ehalsomyndigheten.se/Documents/statistik/lakemedelsforsaljning_Q1Q2_2012.
pdf.
5. Anthony M, Lee KY, Bertram CT, Abarca J, Rehfeld RA, Malone DC, Freeman M,
Woosley RL: Gender and age differences in medications dispensed from a
national chain drugstore. J Womens Health (Larchmt) 2008, 17(5):735–743.
6. Correa-de-Araujo R, Miller GE, Banthin JS, Trinh Y: Gender differences in
drug use and expenditures in a privately insured population of older
adults. J Womens Health (Larchmt) 2005, 14(1):73–81.
7. Owens GM: Gender differences in health care expenditures, resource
utilization, and quality of care. J Manag Care Pharm 2008, 14(3 Suppl):2–6.
8. Bardel A, Wallander MA, Svardsudd K: Reported current use of prescription
drugs and some of its determinants among 35 to 65-year-old women in
mid-Sweden: A population-based study. J Clin Epidemiol 2000, 53(6):637–643.
9. Roe CM, McNamara AM, Motheral BR: Use of chronic medications among
a large, commercially-insured US population. Pharmacoepidemiol Drug Saf
2002, 11(4):301–309.
10. Stock SA, Stollenwerk B, Redaelli M, Civello D, Lauterbach KW: Sex
differences in treatment patterns of six chronic diseases: an analysis
from the German statutory health insurance. J Womens Health (Larchmt)
2008, 17(3):343–354.
11. Fernandez-Liz E, Modamio P, Catalan A, Lastra CF, Rodriguez T, Marino EL:
Identifying how age and gender influence prescription drug use in a
primary health care environment in Catalonia, Spain. Br J Clin Pharmacol
2008, 65(3):407–417.12. Hofer-Duckelmann C: Gender and polypharmacotherapy in the elderly:
a clinical challenge. Handb Exp Pharmacol 2012, 214:169–182.
doi(214):169–182.
13. Redondo-Sendino A, Guallar-Castillon P, Banegas JR, Rodriguez-Artalejo F:
Gender differences in the utilization of health-care services among the
older adult population of Spain. BMC Public Health 2006, 6:155.
14. Dunnell K, Fitzpatrick J, Bunting J: Making use of official statistics in
research on gender and health status: recent British data. Soc Sci Med
1999, 48(1):117–127.
15. Schappert SM, Burt CW: Ambulatory care visits to physician offices,
hospital outpatient departments, and emergency departments: United
States, 2001–02. Vital Health Stat 2006, 159:1–66.
16. Thorell K, Skoog J, Zielinski A, Borgquist L, Halling A: Licit prescription drug
use in a Swedish population according to age, gender and socioeconomic
status after adjusting for level of multi-morbidity. BMC Public Health 2012,
12:575–2458.
17. Allebeck P, Moradi T, Jacobsson A: Sjukdomsbördan i Sverige och dess
riskfaktorer. 2006. http://www.folkhalsomyndigheten.se/pagefiles/12245/
A20064_dalys0606.pdf.
18. The Swedish National Institue of Public Health: The National Bord of
Health and Welfare. Folkhälsorapport 2012. 2012. http://www.fhi.se/
PageFiles/14572/2012-3-6-Folkhalsan-i-Sverige-Arsrapport-2012.pdf.
19. Animated population pyramids 1968–2010. 2013.https://www.h5.scb.se/
kommunfakta/pyramider/index.asp.
20. Wirehn AB, Ostgren CJ, Carstensen JM: Age and gender differences in the
impact of diabetes on the prevalence of ischemic heart disease: a
population-based register study. Diabetes Res Clin Pract 2008,
79(3):497–502.
21. Starfield B, Weiner J, Mumford L, Steinwachs D: Ambulatory care groups: a
categorization of diagnoses for research and management. Health Serv
Res 1991, 26(1):53–74.
22. Zielinski A, Kronogard M, Lenhoff H, Halling A: Validation of ACG Case-mix
for equitable resource allocation in Swedish primary health care.
BMC Public Health 2009, 18(9):347–2458.
23. Weiner JP, Starfield BH, Steinwachs DM, Mumford LM: Development and
application of a population-oriented measure of ambulatory care
case-mix. Med Care 1991, 29(5):452–472.
24. Orueta JF, Lopez-De-Munain J, Baez K, Aiarzaguena JM, Aranguren JI,
Pedrero E: Application of the ambulatory care groups in the primary care
of a European national health care system: does it work? Med Care 1999,
37(3):238–248.
25. The World Health Organization. 2011. http://www.whocc.no/atc/structure_
and_principles/.
26. Murray CJ, Lopez AD: Global mortality, disability, and the contribution of
risk factors: global Burden of Disease Study. Lancet 1997,
349(9063):1436–1442.
27. Murray CJ, Lopez AD: Mortality by cause for eight regions of the world:
global Burden of Disease Study. Lancet 1997, 349(9061):1269–1276.
28. Murray CJ, Lopez AD: Alternative projections of mortality and disability
by cause 1990–2020: Global Burden of Disease Study. Lancet 1997, 349
(9064):1498–1504.
29. Murray CJ, Lopez AD: Regional patterns of disability-free life expectancy
and disability-adjusted life expectancy: global Burden of Disease Study.
Lancet 1997, 349(9062):1347–1352.
30. Medical Products Agency, book of prescription drugs. 2014. http://www.
lakemedelsverket.se/english/.
31. Medical Products Agency, guidelines of treatment. 2014. http://www.
lakemedelsboken.se/.
32. U.S. Department of Health and Human Services National Institue of
Health. 2007. http://www.nih.gov/news/pr/apr2007/nhlbi-03.htm.
33. Galdas PM, Cheater F, Marshall P: Men and health help-seeking behaviour:
literature review. J Adv Nurs 2005, 49(6):616–623.
34. Orzella L, Chini F, Giorgi Rossi P, Borgia P: Physician and patient
characteristics associated with prescriptions and costs of drugs in the
Lazio region of Italy. Health Policy 2010, 95(2–3):236–244.
35. Weng SS, Chen YH, Lin CC, Keller JJ, Wang IT, Lin HC: Physician characteristics
and prescription drug use during pregnancy: a population-based study.
Ann Epidemiol 2013, 23(2):54–59.
36. Glaeske G, Gerdau-Heitmann C, Hofel F, Schicktanz C: Gender-specific drug
prescription in Germany“ results from prescriptions analyses. Handb Exp
Pharmacol 2012, 214:149–167. doi(214):149–167.
Skoog et al. BMC Public Health 2014, 14:329 Page 7 of 7
http://www.biomedcentral.com/1471-2458/14/32937. Lipton RB, Serrano D, Holland S, Fanning KM, Reed ML, Buse DC: Barriers to
the diagnosis and treatment of migraine: effects of sex, income, and
headache features. Headache 2013, 53(1):81–92.
38. Piccinelli M, Wilkinson G: Gender differences in depression. Critical review.
Br J Psychiatry 2000, 177:486–492.
39. Riedel N, Fuks K, Hoffmann B, Weyers S, Siegrist J, Erbel R, Viehmann A,
Stang A, Scheiner J, Dragano N: Insomnia and urban neighbourhood
contexts–are associations modified by individual social characteristics
and change of residence? Results from a population-based study using
residential histories. BMC Public Health 2012, 12:810–2458.
40. Woosley JA, Lichstein KL, Taylor DJ, Riedel BW, Bush AJ: Predictors of
perceived sleep quality among men and women with insomnia. Behav
Sleep Med 2012, 10(3):191–201.
41. Ferguson JA: Prescribing practices and patient sex differences. J R Soc
Health 1990, 110(2):45–49.
doi:10.1186/1471-2458-14-329
Cite this article as: Skoog et al.: Can gender difference in prescription
drug use be explained by gender-related morbidity?: a study on a
Swedish population during 2006. BMC Public Health 2014 14:329.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
